196,214 research outputs found
Hypogonadism in male and female: which is the best treatment?
No full textINTRODUCTION: Subjects with hypo- or hypergonadotropic hypogonadism need hormone replacement therapy (HRT) to initiate puberty and maintain it with a normal hormonal status. While general recommendations for the management of HRT in adults have been published, no systematic suggestions focused on adolescents and young adults. The focus of this review is the HRT in males and females with hypogonadism, from puberty to late reproductive age, covering the different management options, encompassing sex steroid or gonadotropin therapy, with discussion of benefits, limitations and specific considerations of the different treatments. EVIDENCE ACQUISITION: We conducted an extensive search in the 3 major scientific databases (PubMed, EMBASE and Google Scholar) using the keywords "hormonal replacement therapy," "hypogonadism," "bone mineral density," "estradiol/testosterone," "puberty induction," "delayed puberty." Case-control studies, case series, reviews and meta-analysis published in English from 1990 to date were included. EVIDENCE SYNTHESIS: By considering the available opportunities for fertility induction and preservation, we hereby present the proposals of practical schemes to induce puberty, and a decisional algorithm to approach HRT in postpubertal adolescents. CONCLUSIONS: A condition of hypogonadism can underlie different etiologies involving the hypothalamic-pituitary-gonadal axis at different levels. Since the long-terms effects of hypogonadism may vary and include not only physical outcomes related to sex hormone deficiencies, but also psychological problems and implications on fertility, the initiation, maintenance and consolidation of puberty with different pharmaceutical options is of utmost importance and beside pubertal development, optimal uterine and testicular growth and adequate bone health should consider also the psychosocial wellbeing and the potential fertility
Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years.
No full textMalignant insulinoma, a very rare cause of pediatric hypoglycemia
No full textHypoglycemia; Insulinoma; Neuroendocrine tumor; Seizure
Final height (FH) in 77 patients af fected by constitutional delay of growth and puberty (CDGP) variously treated
No full textThe present study retrospectively collected data of 77 pts (54 m, 23 f) with
CDGP followed in 9 Italian centres. Despite similar characteristics at diagnosis,
the pts underwent different diagnostic and therapeutic protocols. Inclusion
criteria: all pts had at diagnosis short stature and idiopathic delayed puberty.
At diagnosis age was 13.8±1.0 yrs in males, height (Ht) sds -2.5±0.6. In females age 13.1±0.9 yrs and Ht sds -2.5±0.6. Protocols. 42 pts were tested
for GHD and the 32 (25 m, 7 f) with deficient secretion received GH therapy for at least 2yrs. The 11 non GHD pts were given either no treatment (3 m, 3
f) or testo. depot for 3-12 months (5 m). The 35 pts deliberately not tested for
GHD received either no treatment (15 m, 13 f) or testo. (7 m).
In males FH (° p=0.004) and ΔFH-target Ht sds (°p=0.05) were higher in the
GH treated group than the testo treated group. In females there were no significant
differences with tendentially better results in the untreated group.
In males 70.8% of the GH treated and 70.6% of the untreated group reached a
FH above target Ht vs 18.2% of the testo. treated group (p=0.007). In females
1/7 in the GH treated vs 10/16 in the untreated group reached a FH above
target Ht (p=0.04). In conclusion the management of pts with CDGP are not
uniform among Pediatric Endocrinologists. In males a non significant better
result vs untreated patients was obtained in the patients treated with GH after
a diagnosis of GHD, while testosterone treated patients reached a significantly
worse result. In females GH therapy did not affect the final result
Identification of two novel mutations in the first Sicilian APECED patient with no R203X mutation in AIRE gene and review of Italian APECED genotypes.
No full text
Post vaccine acute disseminated encephalomyelitis as the first manifestation of chromosome 22q11.2 deletion syndrome in a 15-month old baby: a case report
No full textWe describe a case of a 15-month-old female child admitted to our hospital because of fever, rash, neurological signs (oscillation between states of irritability and drowsiness), palpebral edema and drooping eyelid, appeared 10 days after the vaccination for measles, mumps and rubella. Brain MRI images showed multiple bilateral hyperintense lesions in the white matter typical of acute disseminated encephalomyelitis (ADEM), an autoimmune demyelinating disorder with inflammatory lesions of the central nervous system, due to viral antigens or vaccines. In the mean time, because of patient's vague phenotypic manifestations, suggestive of a genetic defect, array comparative genomic hybridization was carried out which showed the presence of a microdeletion 22q11.21, linked to the DiGeorge syndrome. Our case suggests that pediatric cases of post-vaccination ADEM, in which neurological signs persist, should be investigated for genetic phenotypical features, in order to exclude the presence of a genetic syndrome or disease
Inaccuracy of IGFBP-3 assessment in the diagnosis of growth hormone deficiency (GHD) from childhood to young adulthood: association to low GH-deficiency of IGF-II and presence of circulating IGFBP-3 18 kD fragment
No full textDr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
The risk of diabetes mellitus in children born small for gestational age and treated with recombinant growth hormone
No full text- …
